Terms: = Prostate cancer AND EML4, ENSG00000143924, 27436
7 results:
1. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract] [Full Text] [Related]
2. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
[TBL] [Abstract] [Full Text] [Related]
3. [Alterations of ALK gene and protein expression in prostatic cancer and its clinical significance].
Song R; Ren G; Liu X; Zhang Y
Zhonghua Bing Li Xue Za Zhi; 2015 Jun; 44(6):382-5. PubMed ID: 26704831
[TBL] [Abstract] [Full Text] [Related]
4. Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.
Micci F; Panagopoulos I; Thorsen J; Davidson B; Tropé CG; Heim S
PLoS Biol; 2014 Feb; 12(2):e1001784. PubMed ID: 24504521
[TBL] [Abstract] [Full Text] [Related]
5. Morphologic features of carcinomas with recurrent gene fusions.
Qi M; Li Y; Liu J; Yang X; Wang L; Zhou Z; Han B
Adv Anat Pathol; 2012 Nov; 19(6):417-24. PubMed ID: 23060067
[TBL] [Abstract] [Full Text] [Related]
6. [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du cancer].
André T; Wislez M; Goncalves A; de La Motte Rouge T; Blay JY; Massard C; Bay JO;
Bull Cancer; 2010 Dec; 97(12):1551-62. PubMed ID: 21220230
[TBL] [Abstract] [Full Text] [Related]
7. Non-solid oncogenes in solid tumors: eml4-ALK fusion genes in lung cancer.
Mano H
Cancer Sci; 2008 Dec; 99(12):2349-55. PubMed ID: 19032370
[TBL] [Abstract] [Full Text] [Related]
